tolvaptan has been researched along with Kidney Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H | 1 |
| Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Kumagai, Y; Sato, N; Shibagaki, Y; Shinagawa, H | 1 |
| Aonuma, K; Chiba, H; Ishizu, T; Namekawa, M; Sai, S; Seo, Y | 1 |
| Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N | 1 |
| Akahoshi, Y; Fujiki, H; Ikeda, T; Iwanaga, Y; Miyazaki, S; Morooka, H; Watanabe, H | 1 |
| Blais, JD; Casteleijn, NF; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Higashihara, E; Leliveld, AM; Ouyang, J; Perrone, RD; Torres, VE | 1 |
| Abe, M; Fukuhara, E; Fukunami, M; Furukawa, Y; Ikeda, I; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Kondo, T; Morita, T; Nakamura, J; Ozaki, T; Sato, Y; Seo, M; Tamaki, S; Yamada, T | 1 |
| Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y | 1 |
| Harman, C | 1 |
4 trial(s) available for tolvaptan and Kidney Diseases
| Article | Year |
|---|---|
Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Kidney Diseases; Male; Tolvaptan; Treatment Outcome | 2017 |
Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Furosemide; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Tolvaptan | 2015 |
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Incidence; Kidney Diseases; Male; Pain; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Single-Blind Method; Time Factors; Tolvaptan | 2017 |
Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction - Prospective Randomized Controlled Study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Diuretics; Female; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tolvaptan; Urea; Ventricular Function, Left; Young Adult | 2017 |
5 other study(ies) available for tolvaptan and Kidney Diseases
| Article | Year |
|---|---|
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left | 2022 |
Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Central Venous Pressure; Fibrosis; Heart Failure; Hemodynamics; Hypertension; Kidney Diseases; Kidney Medulla; Male; Protective Agents; Rats; Rats, Inbred Dahl; Sodium, Dietary; Stroke Volume; Tolvaptan; Ultrasonography; Vascular Resistance | 2019 |
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Kidney Diseases; Male; Piperidines; Quinolones; Rats, Inbred Dahl; Receptors, Vasopressin; Time Factors; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
What new drugs can nephrologists look forward to in the next year or two?
Topics: Amides; Anemia; Antihypertensive Agents; Benzazepines; Drug Administration Schedule; Drug Approval; Drug Combinations; Drug Delivery Systems; Erythropoietin; Ferrosoferric Oxide; Fumarates; Humans; Hyponatremia; Immunosuppressive Agents; Kidney Diseases; Nanoparticles; Nephrology; Renal Dialysis; Renin; Tacrolimus; Tolvaptan | 2007 |